^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ASXL1 mutation + ATM mutation

    i
    Other names: ATM, ATA, ATC, ATD, ATDC, TEL1, TELO1, ATM serine/threonine kinase, ASXL1, ASXL Transcriptional Regulator 1, Additional Sex Combs Like 1, Transcriptional Regulator, Polycomb Group Protein ASXL1, Additional Sex Combs Like Transcriptional Regulator 1, Additional Sex Combs Like 1 (Drosophila), Putative Polycomb Group Protein ASXL1, Additional Sex Combs-Like Protein 1, KIAA0978, BOPS, MDS
    Entrez ID:
    472; 171023
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer. (ASCO 2023)
    In this exploratory analysis, patients with co-occurring ATMm and ASXL1m showed higher tumor response. This signals potential value from ATM and ASXL1 co-mutation predicting efficacy of Venadaparib in PC and warrants further validation. Clinical trial information: NCT04174716.
    Clinical • PARP Biomarker • BRCA Biomarker
    |
    ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • ASXL1 (ASXL Transcriptional Regulator 1) • BRCA (Breast cancer early onset)
    |
    ATM mutation • ASXL1 mutation • BRCA mutation • ASXL1 mutation + ATM mutation
    |
    GuardantOMNI
    |
    venadaparib (NOV 1401)